This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.
QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.
Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise
by Zacks Equity Research
Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.
PacBio (PACB) Inks Research Collaboration for Genome Sequencing
by Zacks Equity Research
PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.
Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.
5 Top Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Coty (COTY), BJ's Restaurants (BJRI), DexCom (DXCM), Livent (LTHM) and D.R. Horton (DHI).
DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 54.55% and 4.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom
by Zacks Equity Research
Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog.
Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season, in addition to featuring updated reports on Toyota Motor(TM), Deere & Company (DE) and Starbucks (SBUX).
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and DexCom (DXCM) have performed compared to their sector so far this year.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $130.60, moving -0.04% from the previous trading session.
3 Highly-Ranked Large Cap Stocks to Buy Before Earnings for Big Upside
by Benjamin Rains
Exploring three highly-ranked large-cap stocks--Honeywell, DexCom, and NextEra Energy--that investors might want to buy before their upcoming earnings releases for both near-term and long-term upside.
Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y
by Zacks Equity Research
Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.
NextGen (NXGN) Settles Misrepresentation Allegations for $31M
by Zacks Equity Research
NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here is Why Growth Investors Should Buy DexCom (DXCM) Now
by Zacks Equity Research
DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.
Select Medical (SEM) Up 21% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of improved patient volumes, an expanding healthcare portfolio and solid cash-generating abilities.